Vatiquinone
As of the edition of 20 October 2026, Vatiquinone is a small molecule: in active development; acts on NQO1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2027
- Kind
- Small molecule
- Registered trials
- 15, 3 stopped early
- Disease areas
- Nutrition and metabolism; Nervous system; Inherited and neonatal; Bones, joints and muscles; Heart and blood vessels; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Vatiquinone.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| NQO1 | NAD | P15559 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 0 | 0 | 0 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 6 | 4 | 0 | 2 |
| Phase 3 | 5 | 2 | 2 | 1 |
| All trials | 15 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| PTC Therapeutics | Lead sponsor of trials | 2014 to now |
| Edison Pharmaceuticals | Lead sponsor of trials |